- Home
- ZCMD vs PPBT Comparison
ZCMD vs PPBT Comparison
Compare ZCMD & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZCMD | PPBT |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZCMD | PPBT |
|---|---|---|
| Price | $1.00 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.41 |
| 52 Week High | $11.96 | $5.18 |
Technical Indicators
Market Signals| Indicator | ZCMD | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 41.39 |
| Support Level | $0.72 | $1.35 |
| Resistance Level | $0.97 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 59.72 | 18.92 |
Price Performance
Historical ComparisonAbout ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.